ArticleJournal of hematology & oncology2023

First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors.

Yuanyuan Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.